Strategic Collaboration to Advance Viral Vector Manufacturing
Virica Biotech, a specialist in cell-enhancing technologies for viral vector production, has announced a strategic collaboration with FUJIFILM Biosciences under the Canada–Japan Corporate Co-Innovation Program, supported by the National Research Council of Canada Industrial Research Assistance Program, this initiative combines funding and advisory support to accelerate innovation in adeno-associated virus (AAV) manufacturing, with a focus on optimizing Virica’s Viral Sensitizer (VSE™) technology for use with FUJIFILM Biosciences’ BalanCD HEK293 media system, aiming to deliver enhanced productivity and scalability for global academic and commercial AAV producers
Addressing Challenges in AAV Manufacturing
Adeno-associated virus vectors are a critical component of modern gene therapy, enabling in vivo gene delivery for a wide range of therapeutic applications, however, the manufacturing of AAV vectors remains complex, costly, and difficult to scale, as the number of gene therapy programs continues to expand and target broader patient populations, the demand for high-quality AAV vectors is increasing rapidly, existing production methods often struggle to meet these requirements efficiently, creating bottlenecks in supply and increasing cost pressures, this collaboration seeks to address these challenges by improving yield, consistency, and scalability through advanced cell culture and enhancement technologies
Combining Complementary Technologies
The partnership leverages the complementary strengths of both organizations, with Virica Biotech contributing its proprietary VSE™ technology designed to improve viral vector production by mitigating cellular defense mechanisms, while FUJIFILM Biosciences brings extensive expertise in cell culture media development, particularly its BalanCD HEK293 system optimized for suspension HEK293 cells, by integrating high-performance media with advanced enhancer formulations, the collaboration aims to create a powerful, ready-to-use solution that significantly boosts AAV productivity without requiring major process changes
Optimization Through Advanced Scientific Platforms
To achieve optimal performance, Virica will utilize its High-Throughput Virology (HTV™) platform alongside Design-of-Experiments (DoE) methodologies and analytical testing workflows, these tools enable rapid screening and optimization of VSE™ formulations and process parameters, ensuring compatibility with FUJIFILM Biosciences’ media system, this data-driven approach allows researchers to identify the most effective conditions for viral vector production, reducing development timelines and improving overall manufacturing efficiency
Role of NRC IRAP in Supporting Innovation
The collaboration is supported by the National Research Council of Canada Industrial Research Assistance Program, which provides both funding and expert advisory services, this support underscores the importance of international cooperation in advancing biotechnology innovation, particularly in areas with significant impact on global healthcare, by facilitating collaboration between Canadian and Japanese organizations, the program helps accelerate the development of technologies that can enhance therapeutic production and accessibility worldwide
Enhancing Productivity and Reducing Costs
One of the primary objectives of the collaboration is to increase AAV production yields while reducing the cost of goods, by combining VSE™ enhancers with BalanCD HEK293 media, the partners aim to create a more efficient manufacturing process that delivers higher output with greater consistency, this improvement is critical for making gene therapies more commercially viable and accessible to patients, as lower production costs can translate into more affordable treatments and broader adoption
Leadership Insights on Collaboration Goals
Jean-Simon Diallo emphasized the strategic importance of the partnership, noting that it builds on the recent launch of the CellVantage™ AAV off-the-shelf enhancer, he highlighted the goal of delivering further productivity gains specifically within the FUJIFILM Biosciences BalanCD HEK293 system, reinforcing Virica’s commitment to advancing viral vector manufacturing technologies and supporting the growth of the gene therapy sector
FUJIFILM Biosciences’ Integrated Solutions Approach
Yutaka Yamaguchi highlighted the company’s commitment to providing integrated solutions that combine high-performance media with enabling technologies, he noted that optimizing Virica’s VSE-based enhancers within the BalanCD HEK293 system will offer customers an easy-to-implement solution for improving AAV yields and enabling efficient scale-up, this approach aligns with FUJIFILM Biosciences’ broader strategy of delivering comprehensive tools that support the entire biopharmaceutical development process
Delivering Ready-to-Use Solutions for the Market
A key outcome of the collaboration will be the development of tailored VSE™ formulations designed specifically for use with FUJIFILM Biosciences’ media system, these formulations are intended to be offered as off-the-shelf solutions, allowing end users to adopt them with minimal modifications to existing processes, this ease of implementation is expected to accelerate adoption across both academic and commercial settings, enabling faster scale-up and more efficient production of viral vectors
Supporting the Growth of Gene Therapy and Vaccines
The collaboration has broader implications for the development of cell and gene therapies as well as vaccines, by improving the efficiency and scalability of viral vector manufacturing, the partnership supports the advancement of innovative treatments for a wide range of diseases, including rare genetic disorders and cancer, enhanced production capabilities can help ensure a reliable supply of critical therapeutic components, enabling researchers and manufacturers to bring new treatments to market more quickly
Virica Biotech’s Role in Advancing Bioprocessing
Virica Biotech focuses on developing cell enhancers that improve the yield and quality of viral vectors, its VSE™ technology addresses production inefficiencies caused by cellular defense mechanisms, enabling higher yields and reduced costs, in addition to providing off-the-shelf products, the company offers services that leverage its HTV™ platform and optimization expertise to help clients identify optimal production conditions, this dual approach positions Virica as both a technology provider and a strategic partner in bioprocessing innovation
FUJIFILM Biosciences’ Global Expertise
FUJIFILM Biosciences brings decades of experience in cell culture and biopharmaceutical manufacturing, with a history dating back to 1970, the company offers a comprehensive portfolio of products and services that support life sciences research, cell and gene therapy development, and large-scale production of biotherapeutics and vaccines, its global presence and adherence to stringent quality standards, including ISO and cGMP guidelines, make it a trusted partner for researchers and manufacturers worldwide
Commitment to Innovation and Sustainability
Both organizations are committed to advancing innovation while maintaining a focus on sustainability, FUJIFILM Biosciences operates under the broader sustainability framework of FUJIFILM Holdings Corporation, which emphasizes responsible growth and environmental stewardship, by developing more efficient manufacturing processes, the collaboration contributes to reducing resource consumption and environmental impact, supporting the long-term sustainability of the biotechnology industry
Driving the Future of Biomanufacturing
The partnership between Virica Biotech and FUJIFILM Biosciences represents a significant step forward in the evolution of viral vector manufacturing, by combining advanced enhancer technologies with optimized cell culture systems, the collaboration aims to overcome key challenges in scalability and cost, as demand for gene therapies and vaccines continues to grow, such innovations will play a crucial role in enabling the next generation of medical breakthroughs and improving patient outcomes worldwide
Source link:https://www.businesswire.com/
